Twelve different cancer drug compounds in 6 different categories, including mTOR inhibitors, DNA inhibitors, MT inhibitors, HSP90 inhibitors, HDAC inhibitors, and proteasome inhibitors, were used for combination screening. Here, MTOR is linked to cancer.